Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Joinn Laboratories (China) Co's total inventories for the quarter that ended in Mar. 2026 was ¥1,563 Mil. Joinn Laboratories (China) Co's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was ¥1,488 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Joinn Laboratories (China) Co's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was ¥2.58.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Joinn Laboratories (China) Co's Days Inventory for the
three
months ended in Mar. 2026 was 540.02.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Joinn Laboratories (China) Co's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.17.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Joinn Laboratories (China) Co's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 4.71.
Joinn Laboratories (China) Co (SHSE:603127) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Joinn Laboratories (China) Co's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Joinn Laboratories (China) Co's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Joinn Laboratories (China) Co Total Inventories Related Terms
Joinn Laboratories (China) Co Total Inventories Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joinn Laboratories (China) Co Total Inventories Chart
Joinn Laboratories (China) Co Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Joinn Laboratories (China) Co (SHSE:603127) has a Total Inventories of ¥1,563 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Joinn Laboratories (China) Co and its competitors.
Is Joinn Laboratories (China) Co's Total Inventories too high?
Joinn Laboratories (China) Co's current Total Inventories is ¥1,563 Mil. Overall, Joinn Laboratories (China) Co has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Joinn Laboratories (China) Co's Total Inventories compare to TMO and DHR?
Joinn Laboratories (China) Co's Total Inventories of ¥1,563 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Medical Diagnostics & Research company?
A good Total Inventories depends on the Medical Diagnostics & Research industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Joinn Laboratories (China) Co and its competitors. Joinn Laboratories (China) Co's current Total Inventories is ¥1,563 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Joinn Laboratories (China) Co stock overvalued right now?
Based on GuruFocus' analysis, Joinn Laboratories (China) Co (SHSE:603127) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥17.43, compared to a current price of ¥41.54 — trading 138.3% above its estimated fair value. The current Total Inventories is ¥1,563 Mil. Joinn Laboratories (China) Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Joinn Laboratories (China) Co (SHSE:603127), the current Total Inventories is ¥1,563 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Joinn Laboratories (China) Co (SHSE:603127) Overvalued in 2026?
Based on GuruFocus' analysis, Joinn Laboratories (China) Co stock appears to be overvalued.
The current stock price of ¥41.54 is trading 138.3% above its estimated GF Value™ of ¥17.43.
GuruFocus considers Joinn Laboratories (China) Co to be Significantly Overvalued.
Key valuation signals for SHSE:603127:
Total Inventories: ¥1,563 Mil
GF Value™: ¥17.43 vs. price of ¥41.54 (138.3% above fair value)
No single metric tells the full story. See the SHSE:603127 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Joinn Laboratories (China) Co Ltd is a PRC-based company, along with its subsidiary, it is engaged in contract research organisation (CRO) services. It operates in three segments: Non-clinical studies services offer drug safety assessment, drug metabolism and pharmacokinetics (DMPK) studies, and pharmacology and efficacy studies; Clinical trial & related services provide clinical CRO services, co-managed phase I clinical research units, and bioanalytical servicesl services; and Sales of research models engages in the design, production, breeding and sales of research models, non-human primates and rodents. The majority of revenue comes from the Non-Clinical studies services. Its geographical areas are China, the United States, and Other countries, of which the majority are from China.
78GF Score
Get the complete analysis for SHSE:603127
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603127 has been successfully added to your 
